Research Progress of Key Techniques for Severe/Critical Type of Novel Coronavirus Pneumonia

doi:10.13523/j.cb.2002004

China Biotechnology

2020, Vol. 40

Issue (1-2): 78-83 DOI: 10.13523/j.cb.2002004

Orginal Article

Research Progress of Key Techniques for Severe/Critical Type of Novel Coronavirus Pneumonia

PAN Tong-tong,CHEN Yong-ping(

)

Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang Provincial Key Laboratory for Accurate Diagnosis and Treatment of Chronic Liver Diseases, Hepatology Institute of Wenzhou Medical University, Wenzhou 325035, China

Download:

HTML

PDF(433KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

The pneumonia epidemic caused by the new coronavirus (SARS-CoV-2) seriously threatens the health and life of the general public, and has a major impact on China’s economic development and social stability. Because the new coronavirus is highly contagious, spreads fast, and has a high lethality rate, there are no effective vaccines and drugs to prevent and treat it. A small number of patients have developed severe and critical illness or even died. How to accurately resist and block the progression of new coronary pneumonia, and improve the prognosis of patients is the current research hotspot in the medical and health field. This article reviews the recent advances in the latest treatments for pneumonia in severe and critically new coronavirus infections.

Key words： SARS-CoV-2 Antiviral agent Artificial extracorporeal liver support Cellular immunotherapy Gut microecology

Received: 07 February 2020 Published: 27 March 2020

ZTFLH:

Q78

Corresponding Authors: Yong-ping CHEN E-mail: 13505777281@163.com

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Tong-tong PAN
	Yong-ping CHEN

Cite this article:

PAN Tong-tong,CHEN Yong-ping. Research Progress of Key Techniques for Severe/Critical Type of Novel Coronavirus Pneumonia. China Biotechnology, 2020, 40(1-2): 78-83.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2002004 OR https://manu60.magtech.com.cn/biotech/Y2020/V40/I1-2/78

序号	注册号	注册题目	研究单位
1	ChiCTR2000029638	新型重组高效复合干扰素治疗新型冠状病毒(SARS-CoV-2)肺炎的多中心临床随机对照研究	四川大学华西医院
2	ChiCTR2000029609	磷酸氯喹治疗2019新型冠状病毒肺炎疗效的前瞻性、开放性、多中心临床研究	中山大学附属第五医院
3	ChiCTR2000029603	比较ASC09/利托那韦复方片和洛匹那韦/利托那韦(克力芝)对于新型冠状病毒肺炎确诊病例的疗效及安全性的随机、开放、多中心的临床研究	浙江大学医学院附属第一医院
4	ChiCTR2000029600	法匹拉韦治疗新型冠状病毒肺炎患者的安全性和有效性的临床研究	深圳市第三人民医院
5	ChiCTR2000029580	芦可替尼联合输注间充质干细胞治疗重症新型冠状病毒肺炎患者的前瞻性、单盲、随机对照临床研究	华中科技大学同济医学院附属同济医院
6	ChiCTR2000029559	羟氯喹对新型冠状病毒肺炎的治疗疗效研究	武汉大学人民医院
7	ChiCTR2000029548	巴洛沙韦酯、法匹拉韦对比洛匹那韦/利托那韦(克力芝)在新型冠状病毒肺炎患者中的疗效和安全性的随机、对照临床研究	浙江大学医学院附属第一医院
8	ChiCTR2000029544	在接受当前抗病毒治疗下仍持续检出病毒阳性的新型冠状病毒肺炎患者中加用巴洛沙韦酯片或法匹拉韦片的疗效和安全性的随机、对照临床研究	浙江大学医学院附属第一医院
9	ChiCTR2000029542	氯喹对2019新型冠状病毒肺炎的临床疗效评价	中山大学孙逸仙纪念医院
10	ChiCTR2000029541	达芦那韦/考比司他或洛匹那韦/利托那韦片联合胸腺肽a1联合治疗新型冠状病毒肺炎的随机、开放、对照临床研究	武汉大学中南医院
11	ChiCTR2000029539	洛匹那韦/利托那韦治疗武汉新型冠状病毒肺炎轻症患者的疗效和安全性随机、开放、对照的研究	华中科技大学同济医学院附属同济医院
12	ChiCTR2000029468	洛匹那韦/利托那韦(LPV/r)+恩曲他滨(FTC)/丙酚替诺福韦(TAF)用于治疗2019新型冠状病毒肺炎的临床研究	四川省医学科学院·四川省人民医院急诊医学与灾难医学研究所

Table 1 The clinical trial project of the anti-SARS-CoV-2 drugs registered by the ChiCTR

Table 2 The clinical trial project of the stem cell therapies for COVID-19 registered by the ChiCTR


[1]	Huang C, Wang Y, Li X , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020. doi: 10.1016/s0140-6736(20)30183-5. doi: 10.1016/s0140-6736(20)30183-5

[2]	Zumla A, Chan Jf, Azhar Ei , et al. Coronaviruses - drug discovery and therapeutic options. Nature Reviews Drug Discovery, 2016,15:327-347.

[3]	Xu X, Chen P, Wang J , et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences, 2020. doi: 10.1007/s11427-020-1637-5. doi: 10.1007/s11427-020-1637-5

[4]	Riccio F, Talapatra S, Oxenford S , et al. Development and validation of RdRp Screen, a crystallization screen for viral RNA-dependent RNA polymerases. Biology Open 2019,8. doi: 10.1242/bio.037663. doi: 10.1242/bio.037663

[5]	Chu C M, Cheng V C, Hung I F , et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax, 2004,59:252-256.

[6]	Sheahan T P, Sims A C, Leist S R , et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications, 2020,11:222.

[7]	Holshue M L, Debolt C, Lindquist S , et al. First case of 2019 novel coronavirus in the United States. The New England Journal of Medicine, 2020. doi: 10.1056/NEJMoa2001191. doi: 10.1056/NEJMoa2001191

[8]	Chen N, Zhou M, Dong X , et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England), 2020. doi: 10.1016/s0140-6736(20)30211-7. doi: 10.1016/s0140-6736(20)30211-7

[9]	Hassanein T I, Schade R R, Hepburn I S . Acute-on-chronic liver failure: extracorporeal liver assist devices. Current Opinion in Critical Care, 2011,17:195-203.

[10]	Plock J A, Schnider J T, Solari M G , et al. Perspectives on the use of mesenchymal stem cells in vascularized composite allotransplantation. Frontiers in Immunology, 2013,4:175.

[11]	Nikzad R, Angelo L S, Aviles-Padilla K , et al. Human natural killer cells mediate adaptive immunity to viral antigens. Science Immunology, 2019,4. doi: 10.1126/sciimmunol.aat8116. doi: 10.1126/sciimmunol.aat8116

[12]	Zhou K, Wang J, Li A , et al. Swift and strong NK cell responses protect 129 mice against high-dose influenza virus infection. Journal of Immunology (Baltimore, Md: 1950), 2016,196:1842-1854.

[13]	Sivori S, Meazza R, Quintarelli C , et al. NK cell-based immunotherapy for hematological malignancies. Journal of Clinical Medicine, 2019,8(10):1702.

[14]	Groves H T, Cuthbertson L, James P , et al. Respiratory disease following viral lung infection alters the murine gut microbiota. Frontiers in Immunology, 2018,9:182.

[15]	Hao Q, Dong B R, Wu T . Probiotics for preventing acute upper respiratory tract infections. The Cochrane Database of Systematic Reviews, 2015,CD006895. doi: 10.1002/14651858.CD006895.pub3. doi: 10.1002/14651858.CD006895.pub3

[1]	YUN Tao,GONG Yue,GU Peng,XU Bing-bing,LI Jin,ZHAO Xi-chen. Present Situation and Prospect of International S&T Cooperation between China and Countries Participating in the “Belt and Road” Initiative to Combat COVID-19[J]. China Biotechnology, 2021, 41(7): 110-121.

[2]	CHEN Chen,HU Jin-chao,CAO Shan-shan,MEN Dong. The Development of Antigen Testing for SARS-CoV-2[J]. China Biotechnology, 2021, 41(6): 119-128.

[3]	SHI Rui,YAN Jing-hua. Research Progress of Neutralizing Antibody Drugs against SARS-CoV-2[J]. China Biotechnology, 2021, 41(6): 129-135.

[4]	ZHANG Sai,WANG Gang,LIU Zhong-ming,LI Hui-jun,WANG Da-ming,QIAN Chun-gen. Development and Performance Evaluation of a Rapid Antigen Test for SARS-CoV-2[J]. China Biotechnology, 2021, 41(5): 27-34.

[5]	FAN Yue-lei,WANG Yue,WANG Heng-zhe,LI Dan-dan,MAO Kai-yun. *Research Progress of in Vitro* Diagnostic Technologies for SARS-CoV-2**[J]. China Biotechnology, 2021, 41(2/3): 150-161.

[6]	WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2[J]. China Biotechnology, 2020, 40(5): 1-6.

[7]	XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine[J]. China Biotechnology, 2020, 40(1-2): 57-64.

[8]	LIAO Xiao-yan,CHEN Li-li. The Progress in the Development of COVID-19 Vaccine[J]. China Biotechnology, 2020, 40(12): 8-17.

[9]	LIN Fu-yu,LIU Jin-yi,CHENG Yong-qing. Progress of Interferon α1b Research and Clinical Use Against SARS-CoV-2[J]. China Biotechnology, 2020, 40(12): 1-7.

[10]	CHEN Man,WANG Ai-xian,WU Xue-ying,ZHEN Jun-yi,GONG Mei-wei,GUO Ya,WANG Hui. New Advances in the Application of CAR Cell Therapy in T Cell - acute Lymphoblastic Leukemia[J]. China Biotechnology, 2019, 39(9): 103-107.

Viewed

Full text

Abstract

Cited

Shared

Discussed